View on GitHub

Added entries:

  • (FDA) PIK3CA and AKT somatic variants and PTEN loss of function variants and sensitivity to capivasertib in combination with fulvestrant for patients with breast cancer.
  • (FDA) ROS1 rearrangements and sensitivity to repotrectinib in patients with nsclc.

Revised entries:

  • (FDA) ERBB2 amplification and sensitivity to pembrolizumab in combination with trastuzumab, fluoropyrimidine- and platinum- containing chemotherapy for patients with gastric or gastroesophageal junction (GEJ) adenocarcinoma received an updated indication from the FDA.
  • (FDA) NTRK1/2/3 rearrangements and sensitivity to larotrectinib were changed from translocation to fusion rearrangement type.
  • EGFR p.L858R entries now all contain information for exon and rsid values
  • ABL1 p.T315I entries were revised to have consistent exon and rsid values
  • NRAS p.G12C entries now include an rsid
  • The OncoTree terms and codes were swapped for ATK1 missense variants and p.E17K and sensitivity to MK-2206 in breast cancer and ATM knockdowns in colorectal cancer

Removed entries:

  • (Clinical evidence) PTEN deletions and resistance to pembrolizumab in uterine leimyoma (Peng et al. 2016) had a duplicate entry in the knowledge base, which has been removed.